Novavax, Inc. (NVAX) Stock Analysis
Healthcare · Biotechnology
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M... Read more
TrendMatrix rates Novavax, Inc. (NVAX) as Sell with moderate confidence. The stock trades at $9.40 with +25.4% upside to the $11.71 price target. Overall score: 6.8/10 across 10 analysis dimensions. Reward/risk ratio: 5.1:1.
Passes 3/4 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags). Fails on weak momentum. Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Novavax, Inc. (NVAX) as Sell with moderate confidence. Score 6.8/10.
Take-profit target: $11.71 (+25.4% upside). Reward/risk ratio: 5.1:1. Stop-loss: $8.87.
Risk below floor (0.3 < 3.0).
Novavax, Inc. trades at a P/E of 3.6 (forward -16.4). TrendMatrix value score: 9.3/10. Verdict: Sell.
15 analysts cover NVAX with a consensus score of 3.7/5. Average price target: $14.
What does Novavax, Inc. do?Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to...
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.